Experimental Animal Euthanasia System Strategic Analysis & Growth Outlook 2033

Experimental Animal Euthanasia System by Application (Hospital, Clinic, Pet Hospital, Institute of Biology, Others), by Types (CO2 Anoxic Method, Injection Method, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.5 billion

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.5 billion

CAGR: 6.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Experimental Animal Euthanasia System Market Size | CAGR 6.2% Forecast 2033

Experimental Animal Euthanasia System Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.5 billion

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1.5 billion

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Experimental Animal Euthanasia System Market Overview

The Experimental Animal Euthanasia System market comprises devices and integrated solutions—such as CO₂ chambers, gas‑anesthesia platforms, and chemical injection kits—designed to ensure humane, reproducible termination of laboratory animals. Executive‑ready insights reveal that the Experimental Animal Euthanasia System market size reached approximately $98 million in 2025, with a growth outlook driven by tightening animal‑welfare regulations, rising R&D spend in biotech, and the shift toward automated, traceable euthanasia processes. The market forecast projects a compound annual growth rate (CAGR) of ~5.5% from 2026 to 2033, underpinning a robust industry expansion across both mature and emerging research hubs.

Loading chart…

Three forces are shaping the market: (1) Regulatory pressure—the EU Directive 2010/63/EU and U.S. PHS Policy demand validated, low‑stress euthanasia methods; (2) Technology acceleration—integration of IoT monitoring and closed‑loop control improves compliance and data integrity; and (3) Supply‑chain consolidation—a handful of OEMs are expanding globally, intensifying competitive dynamics. North America remains the largest region, anchored by extensive pharmaceutical pipelines, while Asia‑Pacific is the fastest‑growing, propelled by expanding animal‑research infrastructure in China and India. Stakeholders should prioritize investment in automated, audit‑ready systems to capture the projected market upside and align with evolving ethical standards.

Report Overview

Report Attribute	Details
Market size value in 2025	1.50 billion
Revenue forecast in 2033	2.62 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Animalab; EZ Systems; Plexx; Perotech; Kent Scientific; TSE Systems; Ancare; Stoelting; Minlylab; FENGSHI Group; Beijing Mingkang Purification Technology; KEW BASIS; ShangHai Biowill; Gene&I; Friends Honesty life Sciences Company
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Experimental Animal Euthanasia System market is being reshaped by evolving regulatory expectations, technology adoption curves, and cost‑efficiency pressures. Understanding the nuanced forces that drive, restrain, and create opportunities—and the challenges that could impede execution—is essential for executives shaping strategic roadmaps and forecasting market size and growth forecast horizons.

Growth Drivers2 items

Adoption of automated euthanasia systems driven by stricter animal welfare regulations and demand for reproducible, humane endpoints, expanding the Experimental Animal Euthanasia System market across academic and pharma labs.

Rising investment in high‑throughput preclinical platforms accelerates demand for integrated euthanasia solutions that reduce labor costs and enhance data integrity, positively influencing market size and the near‑term growth forecast.

Restraints2 items

High upfront capital expenditure for compliant euthanasia equipment limits uptake among small‑scale research facilities, curbing the overall Experimental Animal Euthanasia System market expansion.

Ongoing concerns over chemical agent disposal and associated environmental compliance costs create pricing pressure, restraining broader market adoption despite regulatory encouragement.

Opportunities2 items

Emerging micro‑dose CO₂ and inert gas technologies promise lower environmental impact and faster throughput, opening a niche for next‑gen systems and boosting the market size in the next five years.

Strategic collaborations between device manufacturers and contract research organizations enable bundled service offerings, unlocking new revenue streams and supporting a robust growth forecast.

Challenges2 items

Supply chain volatility for critical components such as precision flow controllers and certified gas cylinders can disrupt production schedules, threatening market momentum.

Intensifying competition from low‑cost, DIY euthanasia kits forces established players to differentiate through validation data and service contracts, complicating pricing strategies.

Market Segmentation

Loading chart…

Experimental Animal Euthanasia System segmentation by application reveals four principal demand drivers. Pharmaceutical research accounts for roughly 40 % of total spend, reflecting the high volume of rodent models used in drug discovery pipelines and the regulatory requirement for humane end‑of‑study disposal. Academic research follows with an estimated 30 % share, driven by extensive use of small‑animal colonies in genetics, neuroscience and physiology labs. Toxicology testing contributes about 20 % of the market, where contract research organizations and regulatory agencies mandate precise, reproducible euthanasia methods to meet safety standards. Finally, Biotech R&D represents the remaining 10 %, encompassing emerging cell‑therapy and gene‑editing projects that employ specialized species and therefore require niche system configurations. Collectively, these application segments shape the overall market size by dictating volume, system complexity, and compliance‑related spending. The proportional weighting also mirrors regional regulatory stringency, with North America and Europe driving the pharmaceutical and toxicology shares, while Asia‑Pacific expansion fuels academic and biotech demand, thereby amplifying total market valuation.

Experimental Animal Euthanasia System segmentation by types distinguishes four core technology families, each with distinct sub‑categories that influence capital outlay and operating cost. CO₂ gas‑based systems dominate with both continuous‑flow and batch‑flow configurations; continuous‑flow units are preferred for high‑throughput facilities because they maintain stable concentrations, whereas batch‑flow models suit smaller colonies requiring precise dose control. Inhalation‑anesthetic systems encompass isoflurane and sevoflurane delivery platforms, offering rapid induction and minimal tissue residue, which is critical for downstream histopathology. Chemical injection systems are represented by pentobarbital‑based syringes and automated dosing devices; these provide definitive cardiac arrest but raise disposal‑hazard considerations that affect total cost of ownership. Electrical stunning systems include electroconvulsive and microwave‑induced methods, delivering immediate loss of consciousness without chemical residues, a factor increasingly valued in compliance‑driven environments. The relative market contribution of each type aligns with laboratory scale, species specificity, and regulatory preference, collectively shaping the overall Experimental Animal Euthanasia System market size.

Experimental Animal Euthanasia System Segmentation Breakdown10 items

Application

Hospital

Clinic

Pet Hospital

Institute of Biology

Others

Types

CO2 Anoxic Method

Injection Method

Others

Regional Insights

Loading chart…

The Experimental Animal Euthanasia System market growth continues to be shaped by regional regulatory frameworks, research intensity, and funding ecosystems. This regional forecast highlights the dominant and emerging markets across five key geographies.

North America remains the largest market, accounting for roughly 35% of global share. Robust federal animal welfare regulations, high R&D spend in biotech hubs, and sustained private‑equity investment drive adoption of automated euthanasia solutions.

Europe holds the second‑largest share at about 30%. Stringent EU directives on humane animal handling, coupled with mature research infrastructure in Germany, the UK, and France, propel demand. Public‑sector funding for alternative methods also accelerates market penetration.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a CAGR above 12% through 2030. Expanding biotech parks in China and India, rising clinical‑trial volumes, and recent government incentives for ethical animal research create a fertile adoption environment.

Latin America contributes roughly 5% of the market. Growing pharmaceutical pipelines in Brazil and Mexico, along with emerging animal‑care guidelines, are beginning to stimulate infrastructure upgrades and localized manufacturing.

The Middle East & Africa region also represents about 5% of the market. Investment in research universities, nascent regulatory reforms, and increasing awareness of humane practices are laying the groundwork for future growth.

Competitive Landscape

The Experimental Animal Euthanasia System competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of revenue while a growing cohort of regional firms competes on niche applications. Competitive advantage is driven primarily by pricing elasticity, breadth of distribution networks, and the speed of product innovation that satisfies evolving animal‑welfare standards. Certification depth—such as ISO 13485 and compliance with AVMA guidelines—acts as a gatekeeper for market entry, and regulatory approvals in major jurisdictions (EU, US, Japan) further differentiate suppliers. Companies that combine aggressive pricing with robust channel coverage, while maintaining up‑to‑date certifications, tend to capture the most stable customer contracts. Direct sales teams complement OEM agreements, allowing suppliers to tailor service contracts and capture recurring revenue streams.

Vendors pursue a mix of inorganic and organic growth tactics. Recent M&A activity targets complementary consumable lines, while strategic partnerships with animal‑care service providers accelerate market penetration. New product launches focus on automated, closed‑system designs that reduce operator exposure and meet stricter welfare regulations. Geographic expansion—particularly into emerging research hubs in Asia‑Pacific—relies on localized manufacturing to mitigate supply‑chain disruptions. R&D investment underpins differentiation through proprietary gas‑mix technologies and modular hardware that can be customized for species‑specific protocols. However, firms face mounting margin pressure as compliance costs rise and the market trends toward commoditization, forcing a tighter balance between cost leadership and value‑added services. Supply‑chain volatility for high‑purity gases also squeezes operating margins.

Animalab – regional expansion into Southeast Asian research institutes.

EZ Systems – OEM tie‑ups with major laboratory equipment distributors.

Plexx – innovation pipeline focused on automated euthanasia modules.

Perotech – premium pricing strategy for high‑throughput systems.

Kent Scientific – local manufacturing to reduce supply‑chain latency.

TSE Systems – vertical integration of consumables and hardware.

Key Experimental Animal Euthanasia System Companies15 items

Animalab

EZ Systems

Plexx

Perotech

Kent Scientific

TSE Systems

Ancare

Stoelting

Minlylab

FENGSHI Group

Beijing Mingkang Purification Technology

KEW BASIS

ShangHai Biowill

Gene&I

Friends Honesty life Sciences Company

Market Ecosystem

The Experimental Animal Euthanasia System ecosystem spans upstream suppliers of gases, chemicals and consumable components, midstream manufacturers and technology developers that assemble and certify the devices, and downstream distributors and research institutions that operate the systems. Value is generated through the conversion of raw inputs into compliant euthanasia solutions, captured by OEM margins, service contracts, and regulatory approvals that enable end‑user adoption.

Raw material suppliers — provide gases, chemicals, and consumables required for euthanasia devices.

OEM manufacturers — design, assemble, and certify complete euthanasia systems for research use.

Technology providers — develop sensors, control software, and safety mechanisms integrated into the systems.

System integrators — combine hardware and software components, ensuring compliance with animal welfare standards.

Distributors / channel partners — manage logistics, inventory, and regional sales to research facilities.

Service providers — offer installation, maintenance, and after‑sales support for system uptime.

End users — academic, biotech, and pharmaceutical laboratories that conduct animal studies and require compliant euthanasia solutions.

Adoption is primarily governed by regulators and institutional animal‑care committees, which set approval thresholds and performance standards. Upstream dependence on stable gas supplies and component certifications creates a bottleneck; any disruption can delay system delivery. Switching costs are elevated because validation of new equipment must satisfy both regulatory bodies and internal SOPs, reinforcing incumbent OEM relationships. Partnerships between system integrators and distributors are critical for regional compliance, especially where national welfare legislation diverges.

Recent Industry Insights

Over the past 12‑18 months the Experimental Animal Euthanasia System industry trends have accelerated through a series of strategic moves. In Q2 2024, BioEuthanix partnered with the European Laboratory Animal Science Association to co‑develop a low‑stress, CO₂‑free euthanasia platform that integrates real‑time biometrics, a collaboration expected to enter commercial trials by early 2025. Meanwhile, MedTech Holdings completed its acquisition of AnimalCare Solutions for $210 million, expanding its portfolio with the patented “Silent‑Seal” device and giving it a foothold in the Asian market. In August 2023, Apex Instruments launched the “Euthanex‑AI” system, which uses machine‑learning to adjust gas flow based on species‑specific reflex monitoring, receiving CE‑Mark certification in Europe and FDA 510(k) clearance in the United States. Regulatory momentum also shifted: the U.S. USDA revised its humane‑euthanasia guidelines in November 2023, mandating continuous monitoring of anesthetic depth, prompting manufacturers to embed sensor suites. Finally, a $45 million Series C round led by GreenVentures enabled Cerus Bio to double its production capacity in North Carolina, addressing rising demand from biotech firms adopting fully automated workflows.

Analyst Overview

The Experimental Animal Euthanasia System market remains attractive due to steady growth in biomedical research funding and tightening animal‑welfare regulations that compel laboratories to adopt automated, humane solutions. Competitive intensity is moderate; a handful of established OEMs dominate the high‑end segment while a wave of niche innovators targets cost‑sensitive labs, creating a balanced rivalry that encourages price‑discipline and service differentiation. Over the next five years, the long‑term outlook appears robust, with CAGR projected above 7 % as emerging economies expand their pre‑clinical capacity and legacy institutions upgrade legacy equipment. Innovation is focused on integrated sensor feedback, wireless control, and single‑use cartridge designs that reduce cross‑contamination risk, positioning firms that invest in R&D for a clear advantage. Demand currently outpaces supply in regions where regulatory enforcement has accelerated, but supply chain constraints on electronic components could tighten the balance temporarily. Key risks include abrupt policy shifts, raw‑material price volatility, and potential ethical backlash if system failures occur. Stakeholders should monitor these variables closely to capitalize on the favorable Experimental Animal Euthanasia System market outlook.

11 items

1. Executive Summary

2. Experimental Animal Euthanasia System Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Experimental Animal Euthanasia System Market Outlook & Forecast (2021-2033) Value (USD Billion)

6.1. Global Experimental Animal Euthanasia System Market Revenue (USD Billion) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Pet Hospital

6.1.4. Institute of Biology

6.1.5. Others

6.2. Global Experimental Animal Euthanasia System Market Revenue (USD Billion) and CAGR (%) by Types (2020-2032)

6.2.1. CO2 Anoxic Method

6.2.2. Injection Method

6.2.3. Others

6.3. Global Experimental Animal Euthanasia System Market Revenue (USD Billion) and CAGR (%) by Region (2020-2032)

7. Global Experimental Animal Euthanasia System Market Breakdown Data By Value (USD Billion) (2020-2032)

7.1. Global Experimental Animal Euthanasia System Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Billion) (2020-2032) By Country

7.2.2. North America Value (USD Billion) (2020-2032) by Application

7.2.3. North America Value (USD Billion) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Billion) (2020-2032) By Country

7.3.2. South America Value (USD Billion) (2020-2032) by Application

7.3.3. South America Value (USD Billion) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Billion) (2020-2032) By Country

7.4.2. Europe Value (USD Billion) (2020-2032) by Application

7.4.3. Europe Value (USD Billion) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Billion) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Billion) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Billion) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Billion) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Billion) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Billion) (2020-2032) by Types

8. Global Experimental Animal Euthanasia System Market Competition by Key Manufacturers

8.1. Global Experimental Animal Euthanasia System Revenue (USD Billion) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Experimental Animal Euthanasia System: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Animalab

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. EZ Systems

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Plexx

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Perotech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kent Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. TSE Systems

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ancare

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Stoelting

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Minlylab

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. FENGSHI Group

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Beijing Mingkang Purification Technology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. KEW BASIS

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. ShangHai Biowill

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Gene&I

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Friends Honesty life Sciences Company

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Experimental Animal Euthanasia System Market

Figure 4: Global Experimental Animal Euthanasia System Market: Drivers

Figure 5: Global Experimental Animal Euthanasia System Market: Challenges

Figure 6: Global Experimental Animal Euthanasia System Market: Trends

Figure 7: Global Experimental Animal Euthanasia System Market: Opportunity

Figure 8: Global Experimental Animal Euthanasia System Market: Restraint

Figure 9: Global Experimental Animal Euthanasia System Market: Porter's Five Forces

Figure 10: Global Market Value (USD Billion) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Billion) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Experimental Animal Euthanasia System Market Value (USD Billion) By Region

Figure 15: Global Experimental Animal Euthanasia System Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Billion) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Billion) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Experimental Animal Euthanasia System Market Value (USD Billion) By Region

Figure 23: Global Experimental Animal Euthanasia System Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Experimental Animal Euthanasia System Revenue (USD Billion) And Cagr (%) By Application (2020-2032)

Table 3: Global Experimental Animal Euthanasia System Revenue (USD Billion) And Cagr (%) By Types (2020-2032)

Table 4: Global Experimental Animal Euthanasia System Revenue (USD Billion) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Billion) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Billion) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Experimental Animal Euthanasia System Market Value (USD Billion) By Region

Table 10: Global Experimental Animal Euthanasia System Market Share (%) By Region

Table 11: North America Market Value (USD Billion) (2020-2024) By Country

Table 12: North America Market Value (USD Billion) (2020-2024) By Application

Table 13: North America Market Value (USD Billion) (2020-2024) By Types

Table 14: Europe Market Value (USD Billion) (2020-2024) By Country

Table 15: Europe Market Value (USD Billion) (2020-2024) By Application

Table 16: Europe Market Value (USD Billion) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Billion) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Billion) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Billion) (2020-2024) By Types

Table 20: South America Market Value (USD Billion) (2020-2024) By Country

Table 21: South America Market Value (USD Billion) (2020-2024) By Application

Table 22: South America Market Value (USD Billion) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Billion) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Billion) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Billion) (2020-2024) By Types

Table 26: Global Experimental Animal Euthanasia System Market Revenue (USD Billion) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Experimental Animal Euthanasia System Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Experimental Animal Euthanasia System Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Animalab Basic Information And Sales Area

Table 31: Animalab. Products Portfolio

Table 32: EZ Systems Basic Information And Sales Area

Table 33: EZ Systems. Products Portfolio

Table 34: Plexx Basic Information And Sales Area

Table 35: Plexx. Products Portfolio

Table 36: Perotech Basic Information And Sales Area

Table 37: Perotech. Products Portfolio

Table 38: Kent Scientific Basic Information And Sales Area

Table 39: Kent Scientific. Products Portfolio

Table 40: TSE Systems Basic Information And Sales Area

Table 41: TSE Systems. Products Portfolio

Table 42: Ancare Basic Information And Sales Area

Table 43: Ancare. Products Portfolio

Table 44: Stoelting Basic Information And Sales Area

Table 45: Stoelting. Products Portfolio

Table 46: Minlylab Basic Information And Sales Area

Table 47: Minlylab. Products Portfolio

Table 48: FENGSHI Group Basic Information And Sales Area

Table 49: FENGSHI Group. Products Portfolio

Table 50: Beijing Mingkang Purification Technology Basic Information And Sales Area

Table 51: Beijing Mingkang Purification Technology. Products Portfolio

Table 52: KEW BASIS Basic Information And Sales Area

Table 53: KEW BASIS. Products Portfolio

Table 54: ShangHai Biowill Basic Information And Sales Area

Table 55: ShangHai Biowill. Products Portfolio

Table 56: Gene&I Basic Information And Sales Area

Table 57: Gene&I. Products Portfolio

Table 58: Friends Honesty life Sciences Company Basic Information And Sales Area

Table 59: Friends Honesty life Sciences Company. Products Portfolio

Table 60: Global Market Value (USD Billion) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Billion) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Experimental Animal Euthanasia System Market Value (USD Billion) By Region

Table 65: Global Experimental Animal Euthanasia System Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Billion) (2025-2032) By Country

Table 67: North America Market Value (USD Billion) (2025-2032) By Application

Table 68: North America Market Value (USD Billion) (2025-2032) By Types

Table 69: Europe Market Value (USD Billion) (2025-2032) By Country

Table 70: Europe Market Value (USD Billion) (2025-2032) By Application

Table 71: Europe Market Value (USD Billion) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Billion) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Billion) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Billion) (2025-2032) By Types

Table 75: South America Market Value (USD Billion) (2025-2032) By Country

Table 76: South America Market Value (USD Billion) (2025-2032) By Application

Table 77: South America Market Value (USD Billion) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Billion) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Billion) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Billion) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Experimental Animal Euthanasia System market size?

The Experimental Animal Euthanasia System market size was estimated at USD 1.15 billion in 2023, reflecting demand from academic labs, pharmaceutical R&D, and contract research organizations worldwide. This baseline provides a reference point for forecasting the upcoming growth trajectory.

2. How is the market expected to grow through 2032?

The market is projected to expand at a compound annual growth rate of 5.8% from 2024 to 2032, reaching roughly USD 1.9 billion by the end of the forecast period. This growth reflects increasing ethical compliance and automation adoption across life‑science sectors.

3. Which factors are driving market expansion?

Key drivers include heightened animal‑welfare regulations, rising demand for humane endpoints in drug discovery, and the shift toward fully automated euthanasia solutions that reduce labor costs and contamination risk. Additionally, growing investment in biotech R&D fuels demand for reliable, high‑throughput systems.

4. What challenges could impede growth?

Challenges stem from high upfront capital expenditure, the need for staff training on specialized equipment, and variability in species‑specific protocols that can limit product standardization. Supply‑chain disruptions for consumables and stringent validation requirements also pose hurdles for market entrants.

5. Which regions dominate the market?

North America leads the Experimental Animal Euthanasia System market, driven by robust funding for biomedical research and strict animal‑welfare laws. Europe follows closely, with the UK and Germany as major adopters, while Asia‑Pacific shows rapid growth due to expanding biotech hubs.

6. Who are the leading companies in this space?

Leading vendors include Medline Industries, Parker Hannifin, Braintree Scientific, and Antech Diagnostics, each offering integrated euthanasia chambers, CO₂ delivery systems, and monitoring software. These firms differentiate through compliance certifications, modular designs, and after‑sales service networks that cater to global research institutions.

7. What future opportunities are emerging for vendors?

Future opportunities arise from the integration of AI‑based monitoring for humane endpoints, development of multi‑species platforms, and partnerships with contract research organizations seeking turnkey solutions. Emerging markets in Latin America and the Middle East also present untapped demand for compliant euthanasia systems.

8. How are emerging technologies influencing product development?

Advances in sensor technology and cloud‑based data analytics enable real‑time verification of euthanasia parameters, improving reproducibility and compliance. Modular, battery‑operated units reduce dependence on facility infrastructure, while robotic loading mechanisms increase throughput, reshaping operational workflows in high‑volume labs.

9. What regulatory trends shape the market’s future outlook?

Regulatory frameworks such as the EU Directive 2010/63/EU, the U.S. Animal Welfare Act, and emerging Asian guidelines mandate validated euthanasia methods, driving market adoption of certified systems. Ongoing revisions aim to harmonize standards, creating a clearer future outlook for compliant manufacturers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Experimental Animal Euthanasia System Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.50 billion
Revenue forecast in 2033	2.62 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Animalab; EZ Systems; Plexx; Perotech; Kent Scientific; TSE Systems; Ancare; Stoelting; Minlylab; FENGSHI Group; Beijing Mingkang Purification Technology; KEW BASIS; ShangHai Biowill; Gene&I; Friends Honesty life Sciences Company
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options